GrandOmics Endorses Pacific Biosciences of California (PACB) Sequel System With New Purchase

Pacific Biosciences of California (NASDAQ:PACB) has received a purchase order for its sequel systems from GrandOmics. The purchase order is for five additional sequel instruments that the Chinese company intends to use for precision medicine back home. However, its main goal with the latest purchase is to provide a genetic diagnosis of inherited diseases.

GrandOmics Sequel System Purchase

The purchase does not come as a surprise given that GrandOmics was among the first adopters of Pacific Biosciences sequel systems. The company has also in the past provided services for genome assembly and full-length transcriptome. With the purchase, the company has also confirmed plans to establish a genomics service center in the U.S as it moves to expand its wings on the global scene.

Pressmaster/Shutterstock.com

Pacific Biosciences of California (NASDAQ:PACB) chief executive officer, Dr. Michael W. Hunkapiller, expects the partnership with the Chinese company to continue growing as it is among the first to place multi-instrument orders for the Sequel system. The executive also expects continued support in terms of purchase to act as an endorsement of how reliable the sequel system is in a wide range of applications in the clinical research space.

“As one of the early users of the Sequel System, they have experienced the performance gains achieved through software and chemistry upgrades, and we appreciate the confidence they have shown in the platform by purchasing multiple additional systems, “said Mr. Hunkapiller.

GrandOmics is one of the first Chinese sequencing service providers to have participated in a project that sought to construct the first published Asian Genome. The company has so far helped a number of customers complete genome and transcriptome sequencing projects in animal, plant, and the human genome.

The purchase is a further endorsement of Pacific Biosciences Sequel system that remains the talk of the town on genome sequencing in clinical projects. The system has already proved to be highly reliable and effective in providing high accuracy ultra long reads while being the only DNA sequencing technology able to detect epigenetic changes.

Pacific Biosciences of California (NASDAQ:PACB) was up by 5.28% in Wednesday’s trading session, closing the day at $4.59 a share.

Note: This article is written by Andy Parker and was originally published at Market Exclusive.